STOCKS TELEGRAPH

Tag: ADVM

  • Adverum Biotechnologies Inc. (ADVM) Continues to Rise After Hours. Here’s why?

    After being in the red for over a week, the gene therapy company, Adverum Biotechnologies Inc. (ADVM) became bullish on Wednesday. Gaining only 1.72% in the regular session, the bullish momentum spiked up in the after-hours to secure gains of 5.08%. Thus, ADVM was trading at a price of $1.24 per share in late trading on Wednesday at a volume of 7.21 million shares.

    Source: Financial Times

    What Happened?

    ADVM stock had been in a downtrend for a while now. The stock saw a slight uptick after the company announced positive FDA feedback for a gene therapy study on April 6. But it soon resumed the downtrend which continued till April 12. Hence, after being beaten down for so long, the stock finally rebounded on Wednesday as it entered the green. The momentum escalated in the after-hours session as the stock’s gains increased with investors rallying towards it.

    Since there is no other official announcement from the company, the rebound seems to have been instigated by external factors. Most likely, social media discussions and stock sentiment caused investors to rally towards the stock in order to buy the dip. Hence, as investors began to buy the dip, the stock made a comeback.

    ADVM’s Feedback from FDA

    On April 6, the company announced feedback from FDA on its IND application for commencing a Phase II study evaluating eye disorder gene therapy candidate ADVM-022. Therefore, the company is now looking forward to completing the IND amendment process by the mid of this year to commence the study in Q3 2022.

    Gene Therapy Market

    The outbreak of Covid-19 while wreaking havoc worldwide, has proven exponential in advancing the gene therapy market. Gene and cell therapy are now extensively used in developing vaccines for Covid-19. While the pandemic is propelling the market forward, other contributing factors to its growth are technological advancements, the uptrend in investments in R&D as well as an increasing prevalence of the target diseases.

    The gene therapy market is hence poised for growth at a CAGR of 25.71% to reach $14,824.97 million by 2027.

    ADVM’s Outlook

    With a bullish rating in the market, a strengthening of the leadership team, multiple developments in its pipeline, and $305.2 million in the cash balance, ADVM is also poised for some good growth. The company expects its cash position (year-end 2021) to be enough to fund operations into 2024.

    Conclusion

    In conclusion, ADVM is currently enjoying gains as investors continue to buy its recent dip for making some profits.

  • Early Morning Vibes: 4 Stocks We Like for Thursday

    Early Morning Vibes: 4 Stocks We Like for Thursday

    On January 20, American stock markets closed at new all-time highs. The S&P 500 index rose 1.39% to 3852 points, the NASDAQ rose 1.97%, the Dow Jones added 0.83%. Risk appetite has increased on the back of an improving epidemiological situation in the States, positive expectations from the reporting season, and partly due to the official inauguration of President Joseph Biden. The communications sector was a growth engine for the broader market, surging 3.6% on a strong quarterly report from Netflix.

    Company news

    • Streaming giant Netflix (NFLX: + 16.9%) performed better than expected and management announced that it is considering resuming its share buyback program.
    • Bank of New York Mellon (BK: -7.3%) showed mixed results. Operating expenses were above expectations.
    • Procter & Gamble’s (PG: -1.3%) earnings and earnings exceeded expectations, but the stock still declined on investor concerns about the sustainability of the results.

    Today, global stock exchanges are showing positive dynamics. The first decrees of President Biden only indirectly relate to the economy, so they practically do not affect the stock market. Investor optimism is driven by factors that have been in sight for a long time. Among them are soft monetary policy, prospects for the adoption of a new package of fiscal stimuli, acceleration of the vaccination process.

    Yesterday in the United States, a record number of deaths per day was recorded – 4409. Amazon has offered vaccine assistance to the US government, which has boosted investor confidence in boosting the vaccine campaign. In addition, the first studies point to the effectiveness of the Pfizer vaccine against the British strain of coronavirus.

    The first quarterly reports of S&P 500 companies exceed investor expectations. Currently, the forecast assumes an average EPS decline of 5.9%, while just a week ago, EPS was forecast to fall by 8.8%. Market participants are just beginning to put optimistic expectations in the quotes in relation to reporting, so the upside potential of the S&P 500 remains.

    Economic News

    Noteworthy is the weekly publication of data on the number of initial applications for unemployment benefits (forecast: 910 thousand, previous value: 965 thousand). The unexpected rise in the indicator last week has raised concerns. If this time the market participants get an unpleasant surprise again, then the official report on the labor market for January will be weak.

    Sentiment Index

    The Freedom Finance Sentiment Index climbed to 62 out of 100. The indicator reflects market participants’ hope for a global economic recovery in 2021. Worries about the negative impact of the coronavirus pandemic are starting to wane thanks to the prospect of mass vaccinations.

    Technical picture

    Technically, the S&P 500 is prone to an upward movement. On the eve of the broad market index confidently overcame the historical maximum at 3827 points and continued to move to the upper border of the equidistant channel at 3860 points. Indicators indicate the likelihood of the trend continuation. The nearest resistance is the psychologically significant level of 3900 points.

    Today Top Movers

    ‎Jaguar Health Inc (JAGX), a biotechnology company, surged about 30.48% ‎at $3.81 in pre-market ‎trading Thursday following the declaration of closing of $6.0 million issuance and sale of designation-backed note related to possible tropical disease priority review voucher.‎

    ‎Qutoutiao Inc (QTT) share price soared 39.41% to $3.75 during the early morning ‎trading session on ‎Thursday.‎‎

    ‎InspireMD Inc (NSPR) stock ascended 15.48% at $0.81 in the pre-‎market trading today.‎‎

    ‎BIOLASE Inc (BIOL) gained over 12.14% at $1.08 in pre-market ‎trading on Thursday.‎‎

    Top Upgrades & Downgrades

    BTIG turned bullish on PayPal Holdings Inc. (PYPL), upgrading the stock to “Buy”.

    Diebold Nixdorf Incorporated (DBD) has won the favor of JP Morgan’s equity research team. The firm upgraded the shares from Neutral to Overweight and moved their price target to $16.0, suggesting 43.04% additional upside for the stock.

    Synaptics Incorporated (SYNA) received an upgrade from analysts at JP Morgan, who also set their one-year price target on the stock to $110. They changed their rating on SYNA to Neutral from Underweight in a recently issued research note.

    Earlier Thursday BTIG reduced its rating on Senseonics Holdings Inc. (SENS) stock to Neutral from Buy.

    JP Morgan analysts reduced their investment ratings, saying in research reports covered by the media that it’s rating for Maxar Technologies Inc. (MAXR) has been changed to Neutral from Overweight and the new price target is set at $55.

    Analysts at Berenberg downgraded Citigroup Inc. (C)’s stock to Hold from Buy Thursday.

    Latest Insider Activity

    Virgin Galactic Holdings Inc. (SPCE) CFO, Treasurer Campagna Jonathan Joseph announced the sale of shares taking place on Jan 19 at $31.44 for some 56,305 shares. The total came to more than $1.77 million. 

    Snap Inc. (SNAP) Chief Financial Officer Andersen Derek sold on Jan 19 a total of 1,254,458 shares at $50.43 on average. The insider’s sale generated proceeds of almost $0.44 million. 

    Affirm Holdings Inc. (AFRM) 10% Owner Founders Fund V Management, LL declared the purchase of shares taking place on Jan 15 at $49.00 for some 75,000 shares. The transaction amount was around $3.67 million. 

    Adverum Biotechnologies Inc. (ADVM) Director Machado Patrick bought on Jan 15 a total 78,182 shares at $11.52 on average. The purchase cost the insider an estimated $115,174.

    Important Earnings

    Top US earnings releases scheduled for today include FuelCell Energy Inc. (NASDAQ: FCEL). It will announce its Oct 2020 financial results. The company is expected to report earnings of -$0.04 per share from revenues of $17.05M in the three-month period. 

    Analysts expect Baker Hughes Company (NYSE: BKR) to report a net income (adjusted) of $0.17 per share when the bank releases its quarterly results shortly. Revenue for the fiscal quarter ended Dec 2020 is predicted to come in at $5.42B. 

    Intel Corporation (INTC), due to announce earnings after the market closes today, is expected to report earnings of $1.1 per share from revenues of $17.5B recently concluded three-month period.